State of the State in TB Control
|
|
- Brice Carter
- 5 years ago
- Views:
Transcription
1 State of the State in TB Control Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center
2 Disclosures-Funding NIH (grant) CDC (contract) JHP Pharmaceuticals (grant) Exxon-Mobil (consultant) UpToDate (card author) Novella/NKT Therapeutics (DSMB)
3 In 2014 TB was subdued, Ebola! Ebola! Ebola! was news. Polio spreads! WHO did cry, And that new virus MERS called for Media Live. Two fatal plane crashes on Malaysian Air Chikungunya popped up all over the West, And D68 pneumonia wasn t the best. All of these problems make people shriek, But TB kills as many in about a week.
4
5 TB News in 2014 Continued decline in cases Continued decline in funding to treat cases Smoking and TB still bad New drugs and making old drugs work better Perspective on contact investigations More info on IGRAs Long-term survival after TB
6 Lancet 2014; 384:
7
8 TB in NC US rate (2014) 3.0/100K vs NC /K #29 for incidence rate, #13 for total cases TB is not someone else s problem
9 # Cases NC TB cases Year
10 NC Demographics Thousands Asian/Pacific Islander Hispanic Total FB
11 Foreign-born TB Cases in NC % 40% 30% 20% 10% 0% Year
12
13 Smoking and TB Smoking is associated with higher rates of both TB infection and disease Smoking has also been associated with worse TB treatment outcomes The reasons for these observations are not clearly understood
14 Smoking and TB Investigators obtained alveolar macrophages via bronchoscopy from nonsmokers, exsmokers, and smokers Examined how these macrophages responded when challenged with Mycobacterium tuberculosis O Leary SM et al, AJRCCM 2014; 190:
15 O Leary SM et al, AJRCCM 2014; 190:
16 O Leary SM et al, AJRCCM 2014; 190:
17 O Leary SM et al, AJRCCM 2014; 190:
18 O Leary SM et al, AJRCCM 2014; 190:
19 Smoking and TB Smoking impairs the macrophage response to TB in the lung May explain part of why smokers get more TB and tend to stay smear-positive longer O Leary SM et al, AJRCCM 2014; 190:
20 New Drugs Current treatment for MDR TB is months Multiple, toxic drugs Suboptimal outcomes
21 New Drugs Pretomanid (Pa-824) is a nitroimidazole drug active against M. tuberculosis Mechanism of action is not fully understood; probably has several mechanisms Promising therapy for drug-resistant TB as well as perhaps treatment-shortening for drugsusceptible TB
22 New Drugs Phase 2 study examining a combination of pretomanid, moxifloxacin, and pyrazinamide Evaluated patients from 6 sites in South Africa and 2 sites in Tanzania Pulmonary TB, CD4>200 One group of patients had MDR but had to be susceptible to PZA and moxi Dawson R et al, Lancet 2015; 385:
23 Dawson R et al, Lancet 2015; 385:
24 Dawson R et al, Lancet 2015; 385:
25 Dawson R et al, Lancet 2015; 385:
26 New Drugs Early data, but drug and regimen have potential Looks good for MDR but many MDR are PZAresistant (67% in the group studied here), so not widely applicable
27 Optimizing TB Drugs Current TB drugs were developed in the 50s and 60s Dose of rifampin was primarily based on cost Is it the right dose? Mouse studies suggest that more is better
28 Increasing Rifampin Dose Dose-ranging safety, tolerability, and microbiologic efficacy (phase 2) study Conducted at one of two sites in Cape Town, South Africa Enrolled patients with smear-positive pulmonary TB; if HIV+ had CD4 350 Boeree MJ et al., AJRCCM 2015; 191:
29 Increasing Rifampin Dose Dose-ranging safety, tolerability, and microbiologic efficacy (phase 2) study Conducted at one of two sites in Cape Town, South Africa Enrolled patients with smear-positive pulmonary TB; if HIV+ had CD4 350 Boeree MJ et al., AJRCCM 2015; 191:
30 Boeree MJ et al., AJRCCM 2015; 191:
31 Boeree MJ et al., AJRCCM 2015; 191:
32 Boeree MJ et al., AJRCCM 2015; 191:
33 Boeree MJ et al., AJRCCM 2015; 191:
34 Boeree MJ et al., AJRCCM 2015; 191:
35 Increasing Rifampin Dose Higher doses appeared to be reasonably safe and well tolerated Higher doses also associated with more microbiologic activity Maximum tolerated dose was not reached may try higher! Boeree MJ et al., AJRCCM 2015; 191:
36 What About Rifapentine? Longer half-life than rifampin, so exposure is much higher when rifapentine is given at equivalent doses Mouse models also have suggested increased activity at high doses
37 What About Rifapentine? Phase 2 randomized, controlled trial examining high-dose rifapentine Randomized pulmonary TB patients to one of the following: Rifampin 10 mg/kg daily Rifapentine 10 mg/kg daily Rifapentine 15 mg/kg daily Rifapentine 20 mg/kg daily All subjects got standard HZE Dorman SE et al., AJRCCM 2015; 191:
38 Dorman SE et al., AJRCCM 2015; 191:
39 Dorman SE et al., AJRCCM 2015; 191:
40 Dorman SE et al., AJRCCM 2015; 191:
41 /
42 Risk of TB Among Contacts We often tell people that after TB infection, the risk of TB disease is 5-10% ~2.5-5% during the 2 years after infection ~2.5-5% over the rest of a lifetime These estimates are based on old data Are they still true?
43 Risk of TB Among Contacts Examined contact of pulmonary TB patients in Amsterdam Followup through October 2012 Definitions: Coprevalent: Dx 180 days from index case Incident: Dx>180 days after index case Sloot R et al, AJRCCM 2014; 190: 1044
44 Risk of TB Among Contacts Contact investigations performed similar to how we do them TST read hours Since 2008, positive TSTs are confirmed with a Quantiferon If no IGRA done, TST of 10 mm or more considered positive Contacts with LTBI are offered 3HR, 4R, or 6H Sloot R et al, AJRCCM 2014; 190: 1044
45 Risk of TB Among Contacts 9332 contacts identified 74 (0.8%) had coprevalent TB Of these, 68 were contacts to smear-positive cases 36 incident cases Sloot R et al, AJRCCM 2014; 190: 1044
46
47 Risk of TB Among Contacts 739/4774 (16%) screened contacts had LTBI 57 of these had coprevalent TB not really LTBI 5-year risk of incident or coprevalent TB=9.5% 372/681 contacts with LTBI did not start rx 5-year risk of LTBI in this group 2.4% (95% CI %) Sloot R et al, AJRCCM 2014; 190: 1044
48 Risk of TB Among Contacts Most of the TB found was coprevalent Major benefit of contact investigation is to find these Incidence of TB lower than previously estimated Protective effect of LTBI rx probably limited by adherence Sloot R et al, AJRCCM 2014; 190: 1044
49 IGRAs in TB Contacts The tuberculin skin test has traditionally been used to screen TB contacts, but has a number of limitations Limited published data have supported the use of IGRAS to screen TB contacts Especially in an era of declining resources, we need to understand how these tests perform
50 TBNET Contact Study Multicenter study examining TB contacts in Western Europe Prospective, observational Either a QFT or a TSPOT was done, at the discretion of the site Further evaluation and f/u done per local protocols Zellweger J-P et al, AJRCCM 2015; 191:
51 Zellweger J-P et al, AJRCCM 2015; 191:
52 TBNET Contact Study Overall 27.2% were IGRA+; only 0.5% indeterminate results Extent of contact correlated with proportion with positive IGRA Birthplace outside of Europe also associated with positive IGRA Zellweger J-P et al, AJRCCM 2015; 191:
53 Zellweger J-P et al, AJRCCM 2015; 191:
54 Zellweger J-P et al, AJRCCM 2015; 191:
55 TBNET Contact Study Changing the test cutoffs didn t seem to make a huge difference in ability to predict future TB Latent TB treatment among persons with a positive IGRA was associated with significant reduction in future TB (compared with no treatment) We probably need better tests Zellweger J-P et al, AJRCCM 2015; 191:
56 IGRAs in Immunocompromised TBNET authors examined the relative performance of TST and both IGRAs Recruited patients from 17 centers in 11 European countries Patients were adults (18+) with HIV, chronic renal failure, rheumatoid arthritis, or transplant Also recruited low-risk, immunocompetent controls Sester M et al, Am J Respir Crit Care Med 2014; 190: 1168
57 Sester M et al, Am J Respir Crit Care Med 2014; 190: 1168
58 Sester M et al, Am J Respir Crit Care Med 2014; 190: 1168
59 Sester M et al, Am J Respir Crit Care Med 2014; 190: 1168
60 IGRAs in Immunocompromised 11 patients developed active TB during median 1.8 yrs f/u (IQR ) 10 of these had HIV (median CD4 302, all with detectable VL), 1 was a solid-organ transplant recipient All patients who developed TB were born in a medium or high incidence country and had not received LTBI rx Sester M et al, Am J Respir Crit Care Med 2014; 190: 1168
61 IGRAs in Immunocompromised Incidence of active TB after 2 years among persons with positive test and no LTBI rx: TST 1.15/100 person-years QFT 0.71/100 person-years TSPOT 0.88/100 person-years Much lower in persons with negative tests (0.15, 0.11, and 0.17/100 p-y for TST, QFT, TSPOT, respectively) Sester M et al, Am J Respir Crit Care Med 2014; 190: 1168
62 IGRAs in Immunocompromised None of the available tests perform well in these populations IGRAs were not superior to TST in this study All patients who developed TB had a risk factor for TB exposure Testing low-risk persons because of immune compromise probably not a great idea Sester M et al, Am J Respir Crit Care Med 2014; 190: 1168
63 Long-term mortality from TB A small proportion of people with TB die from it acutely In NC % of TB cases died before starting rx 5.7% died in the first 8 weeks 4.4% died prior to completing rx Nguyen LT et al, IJTLD 2011; 15:
64 Nguyen LT et al, IJTLD 2011; 15:
65 Mortality After TB Treatment TB can cause long-term damage to the lungs People who get TB may systematically differ from the rest of the population Does having had TB affect long-term survival?
66 Mortality After TB Treatment TBESC examined this question among patients in TX, MA, and Seattle Compared 2 groups: Patients with active TB dx who completed TB therapy (N=3853) Comparison group with LTBI during the same 10 year period as the cases (N=7282) Used National Death Index to assess mortality as of 2008 Am J Pub Health 2015; 105:
67 Am J Pub Health 2015; 105:
68 Mortality After TB Treatment As of 2008, 20.7% of TB survivors vs. 3.1% of LTBI patients dead Death among TB survivors associated with white race and HIV+ status After adjustment for age, gender, race, HIV status, foreign birth, TB survivors were 7.6 times more likely to die than LTBI patients Am J Pub Health 2015; 105:
69 Mortality After TB Treatment What does this mean? Unlikely that most of the mortality effect is actually due to late effects of TB EP TB not much different than pulmonary TB Long-term effects of lung damage, for example, may be contributing to mortality TB probably a marker for high risk Am J Pub Health 2015; 105:
70 A Little Story Accinelli RA et al, AJRCCM 2015; 191: 1202
71 A Little Story Intervention started in 1985 TB screening with sputum and CXRs DOT for active TB patients LTBI treatment Physician-directed program integrated with community resources Accinelli RA et al, AJRCCM 2015; 191: 1202
72 Accinelli RA et al, AJRCCM 2015; 191: 1202
73
Jeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More informationState of the State in TB Control
State of the State in TB Control Jason Stout, MD, MHS Wake County TB Medical Consultant NC TB Medical Director Division of Infectious Diseases, Duke University Medical Center Disclosures-Funding NIH (grant)
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationLatent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal
Latent Tuberculosis Infection Reporting Instructions for Civil Surgeons Using CalREDIE Provider Portal Civil surgeons are required to report tuberculosis (TB) screening outcomes that result in latent TB
More informationTuberculosis Epidemiology
Tuberculosis Epidemiology TB CLINICAL INTENSIVE COURSE Curry International Tuberculosis Center October 18, 2017 Varsha Hampole, MPH Tuberculosis Control Branch California Department Of Public Health Outline
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationLTBI: Who to Test & When to Treat
LTBI: Who to Test & When to Treat TB Intensive May 10 th, 2016 David Horne, MD, MPH Harborview Medical Center University of Washington DISCLOSURES I have no disclosures or conflicts of interest to report
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationTB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology
TB EPIDEMIOLOGY TB Clinical Intensive Course Curry International Tuberculosis Center September 30, 2015 Varsha Nimbal, MPH Tuberculosis Control Branch California Department of Public Health 1 Outline TB
More informationLTBI Treatment and Anti TNF alpha
LTBI Treatment and Anti TNF alpha Therapy Julie Higashi, MD PhD Director, TB Control Section San Francisco Department of Public Health TNF alpha is important for the immune response against TB Macrophages
More informationNew Tuberculosis Guidelines. Jason Stout, MD, MHS
New Tuberculosis Guidelines Jason Stout, MD, MHS Two New Sets of Guidelines Treatment of Drug-Susceptible Tuberculosis Clinical Infectious Diseases 2016; 63(7): e147-e195 Diagnosis of Tuberculosis in Adults
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More informationFailure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources
Failure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources Sustaining Public Health Capacity in an Age of Austerity Forum on Microbial Threats Board on Global
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationTuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant
Tuberculosis and Diabetes Mellitus Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant Learning Objectives Understand the impact of uncontrolled diabetes mellitus (DM) on TB infection
More informationA look at medical factors that increase the risk for TB disease
A look at medical factors that increase the risk for TB disease Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination CDC Overview The spectrum of M. tuberculosis infection Immune
More informationMultiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationNorthwestern Polytechnic University
Clinical Tuberculosis Assessment by Health Care Provider Clinicians should review and verify the information in the Tuberculosis (TB) Screening Questionnaire (attached). Persons answering YES to any questions
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationPediatric Tuberculosis in Los Angeles County: An Update
Pediatric Tuberculosis in Los Angeles County: An Update Julie Higashi, MD PhD Director, Tuberculosis Control Program March 2, 2019 0 Pediatricians will be the driving force of TB elimination in California
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationScreening and Treatment Recommendations for Persons Exposed to MDR TB
Screening and Treatment Recommendations for Persons Exposed to MDR TB Although all persons at increased risk of tuberculosis (TB) infection should be screened for TB infection per USPTF/CDC guidelines
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationLatent TB Infection (LTBI) Strategies for Detection and Management
Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu
More informationTB Infection Who is Testing and Treating? TB Control and Elimination: Current Dilemma. Span of TB Control: 2010
TB Infection Who is Testing and Treating? Jennifer Flood, M.D., M.P.H. California Department of Public Health Tuberculosis Control Branch Jennifer.Flood@cdph.ca.gov 1 TB Control and Elimination: Current
More informationDetection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges
Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges David Karol, MD, MA Bureau of Prisons, FMC Butner Duke University Medical Center June 26, 2013 No Disclosures
More informationTBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationTreatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015
Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015 Tuberculosis Infection Diagnosis and Treatment April 7, 2015 El Paso, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationTuberculosis Impact in Boston Residents: 2012
Tuberculosis Impact in Boston Residents: 2012 BOSTON PUBLIC HEALTH COMMISSION Infectious Disease Bureau Communicable Disease Control Division Number of TB Cases: Boston, 1995-2012 200 180 160 140 Number
More informationPediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017
Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has the following disclosures
More information5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationA Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment
A Mobile Health Intervention Utilizing Community Partnership to Improve Access to Latent Tuberculosis Infection Treatment Cassandra Garcia, MSN, RN, FNP-BC Mobile Clinic Provider Texas Children s Mobile
More informationTuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED
Tuberculosis WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments COL Paul Keiser LTC James E. Moon LTC Jaime Mancuso LTC Anjali Kunz MAJ Kristopher Paolino MAJ Leyi
More informationEpidemiology of Tuberculosis Denver TB Course
Epidemiology of Tuberculosis Denver TB Course Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver
More informationGuidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors
Summary and Goals On November 13, 2012, the OPTN/UNOS Board of Directors approved a requirement that all potential living kidney donors undergo evaluation for infection with Mycobacterium tuberculosis
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationDisclosures. Current Issues and Controversies in Child and Adolescent Tuberculosis 02/24/2016. NSTC 2016 Annual Meeting
Current Issues and Controversies in Child and Adolescent Tuberculosis Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea Cruz, M.D.] Disclosures Dr.
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationAT HIGH RISK OF PROGRESSING TO ACTIVE TB? Senior Lecturer and Consultant Physician University Hospitals of Leicester UK
HOW WELL DO IGRAS PERFORM IN THE IDENTIFICATION OF PERSONS WHO ARE AT HIGH RISK OF PROGRESSING TO ACTIVE TB? Dr Pranab Haldar MD MRCP Senior Lecturer and Consultant Physician University Hospitals of Leicester
More information2014 TUBERCULOSIS FACT SHEET A Profile of Mecklenburg County Reported Cases
OVERVIEW T uberculosis (TB) is a disease caused by bacteria called Mycobacterium tuberculosis. TB usually affects the lungs, but it can also affect other parts of the body. TB is spread through the air
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationINDEX CASE INFORMATION
Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.
More informationTuberculosis Pathogenesis
Tuberculosis Pathogenesis Renuka Khurana, MD, MPH May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Renuka Khurana, MD, MPH has the following disclosures
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Tuberculosis Pathogenesis Lynn Horvath, MD April 3, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict of interests No relevant
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationSanta Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014
Guidelines to Revisions to the School Mandate and Requirements 1) What are the tuberculosis (TB) screening requirements for school entrance in Santa Clara County? Students must undergo a TB risk assessment
More informationTuberculosis: A Provider s Guide to
Tuberculosis: A Provider s Guide to Diagnosis and Treatment of Active Tuberculosis (TB) Disease and Screening and Treatment of Latent Tuberculosis Infection (LTBI) Alameda County Health Care Services Agency
More informationTuberculosis Exposure, Infection, and Disease Among Children with Medical Comorbidities
Tuberculosis Exposure, Infection, and Disease Among Children with Medical Comorbidities Andrea T. Cruz, MD, MPH, Omar Merchant, Affan Zafar, and Jeffrey R. Starke, MD Department of Pediatrics February
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationMy heart is racing. Managing Complex Cases. Case 1. Case 1
Managing Complex Cases My heart is racing Amee Patrawalla, MD April 7, 2017 Case 1 Rutgers, The State University of New Jersey Rutgers, The State University of New Jersey Case 1 29 year old physician from
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationMultidrug-resistant tuberculosis in children
Multidrug-resistant tuberculosis in children James Seddon Clinical Lecturer Imperial College London UCL-TB and LSHTM TB Centre World TB Day 2015 24th March 2015 Outline Burden Recent studies Preventive
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationTB Transmission, Pathogenesis & Infection Control
TB Transmission, Pathogenesis & Infection Control Bradley Allen, MD, PhD, FACP, FIDSA. 2014 MFMER slide-1 Disclosures Medical Consultant, TB Control Program Indiana State Department of Health Past clinical
More informationScott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer
Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of
More informationAnnual Tuberculosis Report Oregon 2007
Annual Tuberculosis Report Oregon 7 Oregon Department of Human Services Public Health Division TB Program April 8 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-7.. page
More informationThe Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University
The Elimination of Tuberculosis Richard E. Chaisson, MD Center for TB Research Center for AIDS Research Johns Hopkins University Disclosures Spouse owns Merck stock Consultant: Merck Research funding:
More informationHA Convention 2016 : Special Topic Session 3 May 2016
HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis
More informationEssential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective
Essential Mycobacteriology Laboratory Services in the Era of MDR- and XDR-TB: A TB Controller s Perspective James Watt, MD, MPH Acting Chief, Tuberculosis Control Branch California Department of Public
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationContact Investigation
Tuberculosis Ann Raftery, RN, PHN, MSc GHS Learning Objectives Upon completion of this session, participants will be able to: Describe the criteria used and method for determining the infectious period
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationLatent Tuberculosis in Adults: From Testing TO Treatment
Latent Tuberculosis in Adults: From Testing TO Treatment Sergio M. Borgia, MD, MSc., FRCP(C) Infectious Diseases Consultant, WOHS Medical Director, WOHS Tuberculosis Clinic Assistant Clinical Professor,
More informationUpcoming TB Alliance Studies. CPRT DST Review September, 2014
Upcoming TB Alliance Studies CPRT DST Review September, 2014 STAND PaMZ Ph 3 STAND: Phase 3 Trial of the Pa-M-Z Regimen Participants with newly diagnosed smear positive DS- and MDR-TB DS Pa(100mg)-M-Z
More informationTB Contact Investigation
Ann Raftery, RN, PHN, MS Curry International TB Center Overview Contact investigation as a core TB control and elimination activity Components of TB Contact Investigation TB Control Priority Strategies.
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More information2017/2018 Annual Volunteer Tuberculosis Notice
Lewis Center for Educational Research Academy for Academic Excellence Norton Science and Language Academy Business Offices 17500 Mana Road Apple Valley, CA 92307 E-mail: hr@lcer.org 760-946-5414 Fax 760-946-9193
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationTreating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now!
EXCELLENCE EXPERTISE INNOVATION Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now! Barbara J Seaworth, MD, Medical Director, Heartland National TB Center Professor,
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationTuberculosis: The Big Picture And Challenge of Drug-resistance
5 th APHL National Conference on Laboratory Aspects of Tuberculosis August 11-13, 2008 San Diego, California Tuberculosis: The Big Picture And Challenge of Drug-resistance RADM Kenneth G. Castro, M.D.
More informationTherapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB?
Therapeutic TB vaccines Shortening Treatment for (DS- and) DR-TB? Mark Hatherill South African Tuberculosis Vaccine Initiative (SATVI) University of Cape Town, South Africa 1 1. The need for a therapeutic
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More information4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB
Sindy M. Paul, MD, MPH, FACPM May 1, 2012 The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB morbidity, including resistance Identifying people
More informationGlobal, National, Regional
Epidemiology of TB: Global, National, Regional September 13, 211 Edward Zuroweste, MD Chief Medical Officer Migrant Clinicians Network Assistant Professor of Medicine Johns Hopkins School of Medicine Epidemiology
More informationANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012
ANNUAL TUBERCULOSIS REPORT OREGON 211 Oregon Health Authority Public Health Division TB Program November 212 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-211... page
More information8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationCase Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
More informationTuberculosis Elimination
Tuberculosis Elimination Where We ve Been, Where We re Going Mark Lobato, MD New England TB Consultant Division of Tuberculosis Elimination Centers for Disease Control and Prevention Disclosures / Disclaimer
More information